PRIME Journal Vol. 12 Issue 1

news NEWS | 10 January/February 2022 | prime-journal.com he International Society of Aesthetic Plastic Surgery (ISAPS) released the results of its annual Global Survey on Aesthetic/ Cosmetic Procedures, which showcased the impact of the COVID-19 pandemic on aesthetic plastic surgery procedures worldwide throughout 2020. Highlights Plastic surgery procedures for aesthetic purposes decreased by 10.9% overall in 2020, with 77.8% of surgeons globally experiencing temporary practice closures during the COVID-19 pandemic. Nonsurgical procedures (primarily fillers and hair removal treatments) continued to increase, but by lower proportions than seen in previous years (5.7% in 2020, compared to 7.6% in 2019). This resulted in an overall decrease of 1.8% for all procedures. Dr. Arturo Ramirez-Montañana, Chair of ISAPS’ Global Survey Committee said, ‘This downward trend is in line with our survey findings of lower patient demand due to safety and financial concerns during the COVID-19 pandemic. At the same time, many of us have also experienced an increase in demand due to patients’ increased flexibility, the opportunity for a more private recovery and, particularly for facial procedures, the so-called ‘zoom effect’. This has limited the impact of COVID-19 on overall procedures.’ Aesthetic Procedures The most common surgical procedures worldwide remained the same during 2020, with breast augmentation making up 16% of all procedures, liposuction 15.1%, eyelid surgery 12.1%, rhinoplasty 8.4%, and abdominoplasty 7.6%. The top five nonsurgical procedures also remained consistent: botulinum toxin (43.2% of all nonsurgical procedures), hyaluronic acid (28.1%), hair removal (12.8%), nonsurgical fat reduction (3.9%), and photo rejuvenation (3.6%). Around 85% of nonsurgical procedures were performed on women. In spite of the overall reduction in surgeries, rhinoplasty and brow lift surgeries continued to increase, and nonsurgical facial rejuvenation showed a 13.9% increase compared to a decrease in both 2019 and 2018. Overall, nonsurgical procedures increased, except for botulinum toxin, hyaluronic acid, and micro- ablative resurfacing (decreasing by 0.9%, 6.1% and 11.3%, respectively). The most common surgical procedures in men continue to be eyelid surgery, liposuction, gynecomastia, rhinoplasty and ear surgery. At the time of this survey, only 45% of surgeons had seen a return to pre-pandemic patient volume. Dr. Ramirez-Montañana said, ‘Despite the terrible pandemic we are living through, it seems that most aesthetic plastic surgeons are getting back to near-normal practice and I am optimistic about 2021, both for the plastic surgery industry and for surgical and nonsurgical procedures.’ Around-upof news stories in theaestheticandanti-ageing medicine industry Galderma has announced the new label for SCULPTRA® (injectable poly-L-lactic acid (PLLA)), the first and only FDA-approved PLLA facial injectable treatment that helps stimulate the skin’s own collagen production, to smooth facial wrinkles, such as smile lines. The new label approved by the U.S. Food and Drug Administration (FDA) includes higher dilution, the addition of immediate use reconstitution, new injection techniques and the optional addition of lidocaine. These changes provide aesthetic injectors with even more options to administer SCULPTRA safely and effectively. ‘I’ve been using SCULPTRA with my patients for over 10 years and it is my go-to product for collagen stimulation, with natural-looking, long-lasting results that address a number of underlying ageing concerns, such as facial wrinkles and volume loss,’ said Dr. Melanie Palm, MD. ‘Aesthetic injectors will find that the higher reconstitution volume with optional lidocaine can help increase patient comfort, and the immediate use protocol provides greater convenience.’ SCULPTRA delivers gradual, natural-looking results over an average of three treatments spaced at least 3 weeks apart. In a clinical study, 100% of patients still showed improvement in the appearance of wrinkles up to 2 years after last treatment according to investigator evaluation. The new label approval is based on new data from physiochemical studies, as well as results from a randomised, evaluator-blinded, parallel-group, multi-centre study, which evaluated the safety and effectiveness of two different dilutions of SCULPTRA. ANNUAL ISAPSGLOBALSURVEYREVEALS IMPACT OFCOVIDPANDEMIC ONAESTHETICPROCEDURES FDA APPROVAL FOR GALDERMA’S NEW SCULPTRA® LABEL T COVID-19 PRACTICE CLOSURES LEAD TO A 10.9% DECREASE IN SURGICAL PROCEDURES

RkJQdWJsaXNoZXIy MTA4OTE=